Abstract 428P
Background
Solitary Fibrous Tumour (SFT) is a rare soft tissue neoplasm with an intermediate biologic potential. The aim of this study was to investigate clinical and pathological factors as well as peripheral blood counts to determine factors predicting for likelihood of early recurrence and poor survival in extra-meningeal SFTs after surgical resection.
Methods
We retrieved the records of 101 patients that were consecutively diagnosed with SFT from 1996-2019 at the National Cancer Centre Singapore and Singapore General Hospital. 19 patients were excluded from the study, of which 6 had distant metastasis at diagnosis, 5 did not undergo curative surgery and 8 were meningeal SFTs that are known to have a poor prognosis. The remaining 82 cases of extra-meningeal SFTs that underwent curative surgery were retrospectively examined with survival analyses performed using the Kaplan-Meier method and multivariate Cox proportional models.
Results
The cohort consisted of 37 men and 45 women with a median age of 51 years (range, 13-87). The primary site of the tumour was abdominopelvic in 18 (22.0%), limbs/trunk in 27 (32.9%), pulmonary/pleura in 18 (22.0%) and head/neck in 19 (23.2%). Median tumour size was 5.0 cm (range, 1.4-30.0). The 5-year overall survival (OS) and event-free survival (EFS) was 92.4% and 79.2% respectively. On univariate analysis, advanced age was prognostic for worse OS, while an abdominopelvic site, lymphocytosis (>2.2 x 109/L) and monocytosis (>0.56 x 109/L) were prognostic for both worse OS and EFS. On multivariate analysis, only age, abdominopelvic site and monocytosis remained independently prognostic for OS, while abdominopelvic site and monocytosis were retained as independently prognostic factors for EFS (all p < 0.05). Tumour depth, tumour size, resection margin, tumour necrosis and mitotic count were not significantly prognostic.
Conclusions
In extra-meningeal SFT, clinical factors including advanced age and abdominopelvic location indicate poor prognosis. In addition, peripheral monocytosis at diagnosis may serve as a novel and easily obtained biomarker for further prognostication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session
174P - A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study
Presenter: Wenwen Zhang
Session: e-Poster Display Session
175P - A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)
Presenter: Yanhong Gu
Session: e-Poster Display Session
177P - Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
Presenter: Hui-Chuan Sun
Session: e-Poster Display Session
178P - Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
Presenter: Jaekyung Cheon
Session: e-Poster Display Session
179P - Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
Presenter: Yue Han
Session: e-Poster Display Session
180P - Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
Presenter: Su Pin Choo
Session: e-Poster Display Session
181P - Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
Presenter: Weihua Zhi
Session: e-Poster Display Session
182P - Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
Presenter: Qi Li
Session: e-Poster Display Session